GENomic Predictors in A Multi-Ethnic Population With Kidney Disease Study
Launched by WESTERN SYDNEY LOCAL HEALTH DISTRICT · Feb 10, 2025
Trial Information
Current as of July 23, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
The GENomic Predictors in a Multi-Ethnic Population with Kidney Disease Study is designed to better understand kidney disease by collecting samples from participants. This study aims to create a collection of blood, tissue, and urine samples, known as a biobank, which will help researchers discover new ways to predict and diagnose kidney disease. The ultimate goal is to find important markers that can help doctors understand and manage kidney disease more effectively.
To participate in this study, you need to be at least 18 years old and either have kidney disease or have a risk factor for it, such as a family history of kidney issues, high blood pressure, diabetes, or a history of smoking. Participants will be asked to provide blood samples and agree to follow-up over time. It's important to know that the study is currently active but not recruiting new participants, and individuals who cannot provide consent or have a life expectancy of less than six months are not eligible to join. This study is a significant step toward improving kidney health for people from different backgrounds.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age ≥ 18 years old at time of enrolment
- • Able to provide consent
- • Either have kidney disease at time of enrolment or not have kidney disease but has at least one risk factor for kidney disease (eg family history, hypertension, diabetes, smoking, stones, nephrotoxin use)
- • Consent to longitudinal follow up at enrolment
- • Consent to providing blood samples at enrolment
- Exclusion Criteria:
- • Unable or unwilling to provide consent
- • life-expectancy less than 6-months
- • received haematopoietic stem cell transplant in the past 5 years
About Western Sydney Local Health District
Western Sydney Local Health District (WSLHD) is a leading healthcare organization dedicated to delivering high-quality medical services and advancing clinical research within the Western Sydney region. As a prominent sponsor of clinical trials, WSLHD focuses on fostering innovation and improving patient outcomes through rigorous scientific investigation. By collaborating with healthcare professionals, researchers, and community stakeholders, WSLHD aims to enhance the understanding of various health conditions and develop effective treatments, all while ensuring the highest standards of ethical practice and patient safety.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Westmead, New South Wales, Australia
Nedlands, Western Australia, Australia
Sydney, New South Wales, Australia
Westmead, New South Wales, Australia
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported